DermTech (DMTK) Misses Q2 EPS by 3c, beats revenue

DermTech (NASDAQ: DMTK) reported Q2 EPS of ($0.99), $0.03 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $4 million versus the consensus estimate of $3.7 million.

For earnings history and earnings-related data on DermTech (DMTK) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c